U.S. Markets closed
  • S&P 500

    -4.88 (-0.11%)
  • Dow 30

    +73.94 (+0.21%)
  • Nasdaq

    -125.50 (-0.82%)
  • Russell 2000

    -4.91 (-0.21%)
  • Gold

    +11.30 (+0.63%)

    +0.0016 (+0.1398%)
  • 10-Yr Bond

    -0.0210 (-1.25%)
  • Vix

    +0.42 (+2.80%)

    -0.0039 (-0.2793%)

    -0.5110 (-0.4483%)

    -1,978.07 (-3.15%)
  • CMC Crypto 200

    -49.14 (-3.27%)
  • FTSE 100

    +14.25 (+0.20%)
  • Nikkei 225

    +96.25 (+0.34%)

MDNA.TO: Increased Overall Survival in rGBM Patients Seen with High Dose MDNA55…

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

By David Bautz, PhD



Business Update

Updated Data from Phase 2b Trial Presented at Targeting Innate Immunity Congress

On September 25, 2019, Medicenna Therapeutics Corp. (TSX:MDNA) announced the presentation of updated clinical data from the ongoing Phase 2b trial of MDNA55, an IL-4 targeted toxin, in patients with recurrent glioblastoma (rGBM). The Phase 2b clinical trial enrolled a total of 46 rGBM patients experiencing their first or second GBM relapse (NCT02858895). It is a multi-center, open label, single arm study with the primary endpoint of median overall survival (mOS) and a secondary endpoint of objective response rate (ORR) following a single intra-tumoral infusion of MDNA55 in adult rGBM subjects.

The company had previously announced preliminary topline results for the 21 patients enrolled in the ‘low-dose’ cohort, in which patients received a median of 63 μg of MDNA55, with a mOS of 11.8 months. In addition, patients in the low-dose cohort experienced a disease control rate of 74%, with 14/19 patients having their tumors stabilize or decrease in size when compared to nadir (the largest tumor volume measured). Assessment of tumor response from nadir was utilized using the criteria for immunotherapy Response Assessment in Neuro-Oncology (iRANO) (Okada et al., 2015) to account for the phenomenon of pseudoprogression, in which a treated tumor appears to be growing on subsequent scans following treatment (Van Mieghem et al., 2013).

The updated results show that the 12 evaluable patients in the ‘high-dose’ group had a mOS of 16.7 months. In addition, the percentage of patients alive at six, nine, and 12 months was increased compared to the low-dose cohort, as shown in the following figure.

View Exhibit I

A difference in mOS is also seen when examining survival as a function of IL-4R status. For both the low-dose cohort and the combined low-dose and high-dose evaluable patients, IL-4RHigh patients (defined as an ‘H-Score’ > 60 based on immunohistochemistry analysis of IL-4R expression) showed both increased mOS as well as increased survival at six, nine, and 12 months. One other note about the data is that approximately 60% of the rGBM patients seen in this study were classified as ‘IL-4RHigh’, which while lower than what the literature would suggest is still a significant potential market opportunity.

View Exhibit II

Medicenna also reported on tumor control data for the 31 evaluable patients for which there was also OS data. The following figure shows that 25 of 31 (81%) patients saw either stabilization of the tumor or a decrease in tumor size when compared to nadir. There was also an association seen between tumor control and mOS, with those experiencing either tumor shrinkage or stabilization having a mOS of 16.1 months compared to those who saw tumor progression having a mOS of 8.3 months.

View Exhibit III

The mOS data seen thus far is highly encouraging, particularly in comparison to mOS data seen in trials of other rGBM treatments including Avastin®, lomustine, and temozolomide. The following charts show the mOS results seen from previous clinical trials with those agents, which averaged approximately 8-9 months. This compares to the mOS of 11.9 months seen for the first 33 subjects evaluated in the Phase 2b trial of MDNA55, including a mOS of 16.7 months for the first 12 patients evaluated in the high-dose cohort.

View Exhibit IV

Lastly, we believe the results seen thus far with MDNA55 are all the more impressive when considering the patient population included in the trial, particularly when compared to results seen recently from other clinical trials involving rGBM patients conducted by Ziopharm Oncology (ZIOP) and Tocagen Inc. (TOCA). Ziopharm reported mOS of 12.7 months in a study of a transcriptionally regulated human interleukin-12 gene (Chiocca et al., 2019) while Tocagen reported mOS of 11.1 months for a virally delivered cytosine deaminase gene with 5-fluorocytosine (those results were not statistically significant from standard of care). While the mOS numbers look similar to those reported by Medicenna, important differences in inclusion criteria for the Ziopharm and Tocagen studies show that those trials used a more heterogeneous patient population with characteristics known to associate with increased survival.

Medicenna employed strict inclusion criteria for the Phase 2b trial of MDNA55 that included:

1) patients could not be eligible for resection at the time of recurrence
2) patients had to have GBM at recurrence
3) patients needed to have GBM at the initial diagnosis (those with lower grade gliomas were not eligible)
4) patients could not have IDH1 or IDH2 mutations.

Those inclusion criteria are in contrast to the inclusion criteria for the studies conducted by Ziopharm and Tocagen, which included:

1) patients eligible for resection
2) patients with high-grade glioma at recurrence (including GBM and Grade 3 anaplastic astrocytoma)
3) patients originally diagnosed with lower grade glioma but had recurrence with higher grade glioma
4) patients could have IDH1 and/or IDH2 mutations

Surgical resection (Bloch et al., 2012), Grade 3 gliomas (Dong et al., 2015) and IDH1/IDH2 mutations (Zou et al., 2013) are all known to be associated with increased survival in GBM patients compared to those with no surgical resection, Grade 4 gliomas, and no IDH1/IDH2 mutations. Thus, the patient population in the Phase 2b trial of MDNA55 was comprised of patients with worse prognoses than the overall patient populations in the Ziopharm and Tocagen trials. We believe these factors are important to understand and help to differentiate MDNA55 from other GBM therapies currently under development while highlighting what we believe to be impressive results in a very difficult to treat patient population.

We anticipate additional mOS data from the majority of the remaining patients from the high-dose cohort before the end of 2019. The company then anticipates conducting an ‘end-of-Phase 2’ meeting with the FDA to determine the regulatory path forward for MDNA55 and whether the opportunity exists for accelerated approval.


The updated clinical results from the MDNA55 Phase 2b trial further strengthen our belief that the drug could have a significant impact on the treatment of rGBM patients. The mOS of 16.7 months for the first 12 evaluable patients from the high-dose cohort is approximately two times the current standard of care, and we are eager to see if those results are confirmed for the remainder of the patients in that cohort. We are maintaining our valuation of CAD$5.00 per share.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.